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Diacylglycerol kinases (DGKs) are a family of enzymes that catalyze the metabolism of
diacylglycerol (DAG). Two isoforms of DGK, DGKα, and DGKζ, specifically regulate the
pool of DAG that is generated as a second messenger after stimulation of the T cell
receptor (TCR). Deletion of either isoform in mouse models results in T cells bearing a
hyperresponsive phenotype and enhanced T cell activity against malignancy. Whereas,
DGKζ appears to be the dominant isoform in T cells, rationale exists for targeting both
isoforms individually or coordinately. Additional work is needed to rigorously identify the
molecular changes that result from deletion of DGKs in order to understand how DAG
contributes to T cell activation, the effect of DGK inhibition in human T cells, and to
rationally develop combined immunotherapeutic strategies that target DGKs.
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DIACYLGLYCEROL KINASES IN T CELL RECEPTOR SIGNAL
TRANSDUCTION
Diacylglycerol kinases (DGKs) represent a family of enzymes that catalyze phosphorylation of
the membrane lipid sn-1,2 diacylglycerol (DAG) to form phosphatidic acid (PA) (Eichmann and
Lass, 2015). In T cells, DAG is formed downstream of the T cell receptor (TCR) after activation
of the gamma 1 isoform of phospholipase C (PLCγ1) and cleavage of phosphatidylinositol
4,5-biphosphate (PIP2) into DAG and an additional second messenger, inositol 1,4,5-triphosphate
(IP3) (Krishna and Zhong, 2013). Whereas, IP3 is important in facilitating release of calcium
from the endoplasmic reticulum, DAG interacts with other proteins important in TCR signal
transduction, such as Protein kinase C (predominantly θ isoform in T cells, but also isoforms ε
and η; Quann et al., 2011) and the Ras activating protein RasGRP1 (Krishna and Zhong, 2013).
Biochemically, targeting the activity of DGKs in T cells, either by germline deletion, or with
chemical inhibitors, results in enhanced and sustained signaling downstream of T cells, as assessed
by prolonged phosphorylation of downstream molecules, such as extracellular signal-related
kinases 1/2 (ERK1/2; Zhong et al., 2003; Olenchock et al., 2006; Riese et al., 2011). Although,
three isoforms of DGK are known to be present within T cells (DGKα, DGKδ, and DGKζ), only
two, DGKα and DGKζ, are thought to play an important role in facilitating DAG metabolism
downstream of the TCR (Joshi and Koretzky, 2013). The function of DGKδ is unknown in T cells;
its role in facilitating metabolic flexibility between lipid and carbohydrate utilization suggest that
it may regulate pools of DAG unrelated to TCR signaling (Chibalin et al., 2008). The signaling
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changes resulting from the absence of DGKα or DGKζ alter
the transcriptional program of activated T cells. For instance,
generation of the transcription factor AP1, which is dependent
on Ras/ERK signaling, is decreased in stimulated Jurkat T
cells overexpressing DGKζ (Zhong et al., 2002). Similarly, NF-
κB (nuclear factor kappa-ligh-chain-enhancer of activated B
cells), a critical transcription factor activated downstream of
PKCθ in T cells, is present at increased levels after stimulation
of DGKζ-deficient lymphocytes as compared to DGKζ-replete
cells (Schmidt et al., 2013), though other data suggests that
the regulation of NF-κB may, in some instances, be positively
regulated by DGKs (Yang et al., 2016).
The change in activation of transcription factors in stimulated
T cells after manipulation of DGK activity correlates with
changes in T cell activation markers and function. For instance,
overexpression of DGKα or DGKζ in Jurkat T cells results
in decreased expression of the activation marker CD69 after
stimulation through the TCR complex (Sanjuán et al., 2001;
Zhong et al., 2002), and overexpression of DGKα induces a
state of decreased functional activity resembling an anergy-like
state (Zha et al., 2006). In contrast, deletion of DGKα or DGKζ
results in T cells with enhanced production of effector cytokines,
such as IL2 and IFNγ, and enhanced proliferation (Zhong et al.,
2003; Olenchock et al., 2006). Inhibition of DGKα also allows T
cells to overcome TCR signaling defects present in human X-
linked lymphoproliferative disease (XLP-1) resulting from the
loss of SAP [signaling lymphocytic activation molecule (SLAM)-
associated protein (Baldanzi et al., 2011; Ruffo et al., 2016)],
along with uncontrolled effector T cell expansion after exposure
to Epstein Barr virus (EBV) characteristic of this disease (Ruffo
et al., 2016).
TARGETING DIACYLGLYCEROL KINASES
TO ENHANCE T CELL ANTI-TUMOR
ACTIVITY
Given the enhanced functional activity conferred by loss of DGKs
in T cells, our group and others have tested the hypothesis
that these proteins may serve as useful targets for enhancing
T cell anti-tumor activity. Recently, strategies to target negative
regulators of T cells to enhance their anti-tumor activity have
been successfully translated from basic science studies into
clinical care (Byrne et al., 2015; Sharma and Allison, 2015; Shin
and Ribas, 2015; Callahan et al., 2016). Although, antibodies
directed against CTLA-4 and PD-1 are the most prominent
examples of therapies that have generated clinical responses in
human malignancy, there is significant interest in identifying
additional inhibitory regulators of T cells to combine with
existing approaches and to use in instances where blockade of
PD-1 and other immune checkpoints is ineffective (Restifo et al.,
2016). We focused our studies on DGKζ, since that enzyme
appears to represent the dominant isoform in T cells, based
on a direct comparison of TCR signal strength between T cells
deficient in either DGKα or DGKζ (Joshi et al., 2013). Using
an EL4-ova subcutaneous model system to permit tracking of
immune responses, we observed that DGKζ−/− mice had an
increased frequency of tumor rejection, along with a trend toward
increased number of tumor-specific CD8+ T cells (Riese et al.,
2011). Additionally, we demonstrated that adoptively transferred
naïve (Riese et al., 2011) or activated (Riese et al., 2013) tumor-
specific effector T cells displayed increased activation by tumor
and resultant inhibition of tumor growth. While these studies
relied on strong-antigen driven tumor models, it is likely that loss
of DGKs also enhances T cell anti-tumor activity in tumors with
low-grade antigens, since DAG-mediated activation of RasGRP1
regulates the threshold for T cell activation (Das et al., 2009), and
earlier studies implicated a role for Ras in Jurkat T cell activation
mediated by low grade TCR stimulus (Perez de Castro et al.,
2004).
DGKα has also been evaluated as a potential target to improve
T cell activity against tumor, based on the observation that DGKα
is upregulated in certain inhibited T cell conditions, such as
anergy (Zha et al., 2006), and that DGKα is upregulated in tumor-
infiltrating lymphocytes in human renal cell carcinoma (Prinz
et al., 2012). For instance, our own study using adoptive transfer
of CAR (chimeric antigen receptor)-T cells demonstrated similar
increases in efficacy (compared to wild type T cells) between T
cells deficient in DGKα or DGKζ in the treatment of murine
mesothelioma (Riese et al., 2013). Additionally, a study testing
the importance of DGKα in glioblastoma multiforme (GBM)
cells found that concurrent administration of the relatively non-
specific DGKα inhibitor R59022 resulted in decreased growth of
intracranially injected GBM tumors. Although, a preponderance
of evidence suggested that the decreased tumor growth in this
model resulted from inhibition of DGKα within the tumor cells,
modulation of immune activity was not assessed, and could
have been contributory (Dominguez et al., 2013). DGKs also
play a role in limiting the activity of NK cells isolated from
tumors in patients with renal cell carcinoma, since the addition
of either IL-2 or DGK inhibitor (R59022) to culture media
improves the impaired function of tumor-associated NK cells
(Prinz et al., 2014). Recently, a more specific inhibitor for DGKα
has been developed that may be useful to extend these studies
into additional tumor models (Liu et al., 2016). Although a direct
comparison has not to-date been performed comparing tumor
growth in DGKα−/− and DGKζ−/− mice, future studies will
undoubtedly provide additional comparisons between the two
genotypes with respect to T cell anti-tumor immunity.
MECHANISM OF ENHANCED T CELL
ANTI-TUMOR ACTIVITY IN
DGKζ-DEFICIENT T CELLS
Enhanced anti-tumor activity observed in DGKζ-deficient T
cells was initially thought to result from increased cytokine
production generated after TCR stimulation; however, it is clear
that intrinsic insensitivity to inhibitory signals in the tumor
microenvironment is also an important determinant. In broad
terms, T cell inhibitory factors can be broadly separated into
two groups: those that inhibit T cells by directly inhibiting
proximal TCR signal transduction, and those that inhibit T
cells independent of attenuation of TCR signaling. Examples
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of immunosuppressant pathways that facilitate direct inhibition
of TCR signaling include PD-1 (Chemnitz et al., 2004; Parry
et al., 2005; Yokosuka et al., 2012), Lag3 (Okazaki et al., 2011),
Prostglandin E2 (PGE2) (Wehbi and Taskén, 2016), adenosine
2A receptor (Linnemann et al., 2009; Linden and Cekic, 2012),
and as we have recently identified, TGFβ (Arumugam et al.,
2015; Newman et al., 2016). Whereas, PD-1 and TGFβ inhibit
TCR signaling by directly or indirectly recruiting inhibitory
tyrosine phosphatases, such as SHP-1 or SHP-2 (Src homology
region 2 domain-containing phosphatase-1/2) to the cell surface,
adenosine 2A, and PGE2 receptors activate protein kinase A
(PKA) leading to Csk-mediated inhibition of the proximal
activating tyrosine kinase Lck (Newick et al., 2016). In contrast,
Lag3 appears to oppose TCR signaling via a KIEELE motif that
acts through an unclear mechanism (Freeman and Sharpe, 2012).
In either case, these inhibitory factors act to oppose activation
events facilitated by proximal tyrosine protein kinases, such as
Lck or Zap-70, that are responsible for initiating TCR signal
cascades and are upstream of DAG generation. In contrast are
inhibitory factors that act predominantly by inhibiting T cells
independent of TCR activation and DAG generation. These
include a subset of immune checkpoint receptors, such as Tim3
(Jones et al., 2008; Lee et al., 2011), and CTLA-4. Although
some reports have suggested direct proximal inhibition of TCR
mediated by CTLA-4 (Lee et al., 1998), CTLA-4 more likely
functions predominantly as a sink to sequester CD80 and
CD86, the ligands of the co-stimulatory molecule CD28 (Green
et al., 1994; Walunas et al., 1996; van der Merwe et al., 1997;
Collins et al., 2002). T cells deficient in DGKs may demonstrate
differential sensitivity to inhibition mediated by dependently
or independently of TCR signaling (Figure 1, Table 1). For
instance, a test of numerous T cell inhibitory pathways revealed
that, in contrast to wild type T cells, T cells lacking DGKζ
demonstrate reduced inhibition of IFNγ production in the
presence of high concentrations of TGFβ, Prostaglandin E2
(PGE2) or adenosine (Riese et al., 2013). This suggests that
one can predict, in broad terms, how DGK-deficient T cells
will respond to various immunosuppressive pathways within the
tumor microenvironment, in that one would anticipate DGK-
deficient T cells to be insensitive to inhibitors that directly
attenuate TCR signaling, such as PD-1 or Lag3, but sensitive
to inhibitory pathways that do not directly interfere with TCR
signaling, such as Tim3 or CTLA-4. This model also predicts
which immune targets might be optimally paired with agents that
block DGKs, such that one would anticipate little synergy with
direct regulators of TCR signaling, but potential excellent synergy
with TCR-independent inhibitors. Experiments are currently
ongoing to test these hypotheses.
POTENTIAL ISSUES ARISING FROM
TARGETING DGKS
The diverse set of cellular functions governed by DAG and
PA, including signal transduction (Mérida et al., 2008), lipid
biogenesis (Shulga et al., 2013), and membrane trafficking (Cho
and Stahelin, 2005), presents challenges for broadly targeting
DGK activity therapeutically, especially since the enzymatic
specificity of the 10 mammalian DGKs is highly conserved, with
the exception of DGKε (Jennings et al., 2015). Thus, isolation of
a compound with specificity toward an individual isoform may
prove difficult, a problem exacerbated by the paucity of structural
information available about eukaryotic DGKs. Although, a
prokaryotic form of DGK has been solved structurally (Li et al.,
2013), it is sufficiently divergent from eukaryotic isoforms that
it provides little value in predicting active site topography of
eukaryotic DGKs. For instance, prokaryotic DGKA is not limited
to enzymatic activity against lipids, but can also catalyze reactions
using glycerol and water as substrates for phosphorylation
(Ullrich et al., 2011). Therefore, approaches to target non-
catalytic domains of DGKζmay provide the bestmeans to achieve
isoform specificity. The structural domains of DGKζ have been
well defined, and include a C1 domain, a MARCKS domain,
an ankyrin repeat domain, and a C-terminal PDZ-binding
domain (Joshi and Koretzky, 2013). Of these domains, only the
MARCKS domain and ankyrin repeat domain are unique to
DGKζ among the 10 DGK family members (Joshi and Koretzky,
2013). Furthermore, only the MARCKS domain, a substrate
for serine/threonine phosphorylation by PKCα (Topham et al.,
1998), is required for DGKζ function (Santos et al., 2002). Thus,
targeting the MARCKS domain may be an effective strategy
for therapeutic targeting of DGKζ, in a manner that confers
specificity.
Apart from concerns with isotype specificity, therapeutic
targeting of DGKα and DGKζ could result in deleterious “on-
target” effects, such as enhanced cellular proliferation and
autoimmunity. As expected, mice with deletions of both DGKα
and DGKζ generate T cells with enhanced TCR signaling
downstream of DAG, as well as more potent effector functions
after in vitro stimulation relative to single knockouts or wild
type T cells (Guo et al., 2008; Riese et al., 2013). However, the
activated level of Ras/Erk signal transduction in double knockout
mice (DKO) results in thymic lymphomagenesis (Guo et al.,
2008). This pro-malignant potential of enhanced DAG signaling
is consistent with data from human patients with T cell acute
lymphoblastic leukemia (T-ALL), in which RasGRP1, the Ras
activating protein activated by DAG, has been found to be
frequently overexpressed (Hartzell et al., 2013). Thus, caution
must be used if DGK germline deletion (e.g., using CRISPR-based
approaches) is used as a means to target DGKs in adoptive T cell
therapies. Generating auto-immune disease may also be an issue
when targeting DGKs. Although mice deficient in DGKα, DGKζ,
or both do not develop overt autoimmunity, it is likely that the
mice would develop enhanced T cell responses in autoimmune
models such as experimental autoimmune encephalitis (EAE),
especially given the role DGKs play in limiting activation of
Mnk1/2-mediated activation and development of encephalitis in
the EAE model (Gorentla et al., 2013). A possible explanation for
the lack of overt autoimmunity in DGKζ or DKOmicemay be the
concurrent enhanced generation of natural T regs in these mice
(Joshi et al., 2013), although this remains speculative, and raises
the additional consideration that thymic development of T cells
may be impacted by manipulation of DGK activity. For instance,
constitutive expression of a membrane-bound form of DGKα
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FIGURE 1 | Model of enhanced T cell activity in DGK-deficient T cells. DGKα and DGKζ function to metabolize DAG generated downstream of TCR activation.
Deletion of either or both isoforms results in T cells with enhanced TCR signal transduction downstream of DAG and resultant enhanced effector functions (“No
inhibitor”). Loss of DGK confers resistance to inhibitory pathways that function through direct interference of TCR signal transduction, since these inhibitory events
occur proximal to generation of DAG (“Direct TCR Inhibitor”). We predict that T cells deficient in DGKs remain sensitive to inhibitory pathways that mediate their effect
independent of interference with TCR signal transduction (“Non-TCR Inhibitor”), or for pathways that inhibit TCR signaling at rate limiting steps downstream of DAG
formation.
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TABLE 1 | Relative insensitivity to inhibitory stimuli of CD8+ T cells.
Inhibitory stimuli/receptor Inhibitor-mediated fold ↓ in
IFNγ by CD8+ T cell
Does inhibitory pathway directly
impact TCR signaling?
References
WT DGKζ−/−
TGFβ 35x 1x Yes Arumugam et al., 2015
PGE2 2x 1.5x Yes Riese et al., 2013
Adenosine 2x 1.2x Yes Riese et al., 2013
PD-1 4x Unknown Yes Parry et al., 2005
Lag3 2x Unknown Yes Hannier et al., 1998; Huang et al., 2015
Tim-3 None Unknown No Lee et al., 2011
CTLA-4 2x Unknown Uncertain Krummel and Allison, 1995; Walunas and
Bluestone, 1998
leads to accumulation of immature CD8+ “single positive” T
cells within the thymus in addition to peripheral lymphopenia
(Almena et al., 2013), and DKO mice demonstrate a severe
impairment in thymic development of invariant NKT cells, a
subset of innate T cells (Shen et al., 2011). Ongoing experiments
are needed to test whether DGK-deficient mice will developmore
severe disease than wild type counterparts after autoimmune
challenges, and to determine whether subtle alterations are
present in the thymic development of other conventional T cell
subsets.
CONCLUSIONS
As immunotherapeutic approaches come to the forefront of
cancer treatment, there is an increased need to evaluate proteins
and molecules that inhibit the immune system, especially in
T cells. Diacylglycerol kinases should warrant a high degree
of consideration in these targeting strategies, ideally with the
development of small molecule inhibitors. In the meanwhile, it
may be advantageous tomove forward with genemanipulation in
adoptive cellular therapies. The ability to very specifically target
DGKs within only the transferred T cells will minimize systemic
side effects. It will also be possible to include suicide genes to
enable destruction of the transferred T cells, should it become
necessary. A better understanding of the changes that result from
acute and long-term targeting of DGKs should help discern the
effectiveness of this strategy both alone, and in combination with
other therapies designed to induce immune cell activation.
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